Should I buy or sell Illumina stock right now?
13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Illumina in the last twelve months. There are currently 1 sell r...Read more
What is Illumina's stock price forecast for 2023?
13 equities research analysts have issued 12-month price objectives for Illumina's stock. Their ILMN share price forecasts range from $175.00 to $3...Read more
How have ILMN shares performed in 2022?
Illumina's stock was trading at $380.44 at the beginning of 2022. Since then, ILMN stock has decreased by 46.0% and is now trading at $205.62. Vie...Read more
When is Illumina's next earnings date?
The company is scheduled to release its next quarterly earnings announcement on Thursday, February 9th 2023. View our ILMN earnings forecast .Read more
How were Illumina's earnings last quarter?
Illumina, Inc. (NASDAQ:ILMN) announced its quarterly earnings data on Thursday, November, 3rd. The life sciences company reported $0.34 earnings pe...Read more
What guidance has Illumina issued on next quarter's earnings?
Illumina issued an update on its FY 2022 earnings guidance on Thursday, November, 10th. The company provided earnings per share guidance of $2.35-$...Read more
What is Francis deSouza's approval rating as Illumina's CEO?
496 employees have rated Illumina Chief Executive Officer Francis deSouza on Glassdoor.com . Francis deSouza has an approval rating of 92% among t...Read more
What other stocks do shareholders of Illumina own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Illumina investors own include NVIDIA (NVDA) , Alibaba Gr...Read more
What is Illumina's stock symbol?
Illumina trades on the NASDAQ under the ticker symbol "ILMN."Read more
Is Illumina cheap or expensive?
Is Illumina Cheap or Expensive? Investors use a lot of different multiples to figure out if a stock is cheap or expensive. Sometimes that can just create confusion. Take Illumina (NASDAQ: ILMN), for example. The stock is down 60% from its peak to just above $200 per share -- a level it first reached in early 2018.
Where is Illumina located?
The offices of gene sequencing company Illumina Inc are shown in San Diego, California January 11, 2016. REUTERS/Mike Blake/File Photo Reuters
Will Illumina's Grail deal be killed by antitrust regulators?
WASHINGTON (Reuters) - U.S. life sciences company Illumina Inc on Tuesday defended its $7.1 billion acquisition of biotech firm Grail Inc , pledging to keep selling its DNA sequencing services to other firms, as it seeks to head off a potential vote by U.S. antitrust regulators to kill the deal.